Shots:
- The companies have reported the global P-III (REZILIENT3) trial assessing zipalertinib + Pt-based CT vs CT alone in the 1L treatment of 285 adults with previously untreated, locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations
- Trial met its 1EP of PFS, showing improvement with the zipalertinib-containing regimen at interim analysis, with the IDMC recommending unblinding the study based on the data; efficacy & safety monitoring will continue
- Full results will be presented at an upcoming medical conference. Pending FDA discussions, Taiho Oncology, Taiho Pharmaceutical & Cullinan plan to pursue US approval for the zipalertinib combination in the 1L setting
Ref: Businesswire | Image: Taiho Oncology, Taiho Pharmaceutical & Cullinan | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
